

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound that modulates the activity of a catalytic antibody, wherein said compound has a specific affinity for a catalytic site of said antibody, is non immunogenic, and is a ligand that binds to a receptor, said compound being a peptide consisting of amino acid sequence LNRRA (SEQ ID NO:1).

2-4. (Canceled)

5. (Previously Presented) A compound according to claim 1, wherein said compound comprises a peptide derived from the cytokine TNF α .

6. (Withdrawn) A compound according to any one of claims 1 or 24, wherein said compound comprises a peptide derived from thyroglobulin.

7-21. (Canceled)

22. (Previously Presented) A pharmaceutical composition comprising, as the active principle, a compound according to claim 1 in combination with a pharmaceutically acceptable vehicle.

23. (Withdrawn) A pharmaceutical composition according to claim 22, wherein said composition comprises a further active molecule that modifies or stimulates the biological activity of said compound or diminishes any secondary effects of said compound.

24. (Withdrawn) The compound of claim 1, wherein said ligand is a hormone, a drug, or a medication.

25. (Canceled)

26. (Withdrawn) The compound of claim 5, wherein said peptide comprises amino acid sequence IASVY (SEQ ID NO:2).

27. (Withdrawn) The compound of claim 5, wherein said peptide comprises amino acid sequence LFA.

28. (New) A compound that modulates the activity of a catalytic antibody, wherein said compound has a specific affinity for a catalytic site of said antibody, is non immunogenic, and is a ligand that binds to a receptor, said compound being a peptide fragment of TNF-alpha that binds to cell receptor p55.